Insights
Insights From Our Experts
Articles
News Alert: MCIT Implementation Delayed
On Friday, March 12, the Centers for Medicare and Medicaid Services (CMS) issued an Interim Final Rule with Comment (IFC) delaying the effective date of the Medicare Coverage of Innovative Technologies (MCIT) initiative from March 15…
Webinar: Drug Pricing and Reporting Regulatory Updates Part 2
In Part 2 of our Drug Pricing and Reporting Regulatory Updates webinar, EVERSANA revenue experts take a look at the Final Rule, which was released by the Centers for Medicare and Medicaid Services in December 2020.…
Webinar: Drug Pricing and Reporting Regulatory Updates Part 1
Pharmaceutical companies in the U.S. are navigating President Biden’s new administration and legislative changes that are affecting pricing and regulatory actions. One of these changes includes the regulatory freeze ordered for actions made in the final two months of…
The Crush: How Covid-19 Is Impacting Mature Brand Revenue & Long-Term Value
The impact of COVID is reverberating across all aspects of society and business. In the healthcare industry, hundreds of thousands of patients are not getting proper access to and utilization of therapies that can improve their…
How to Determine Price and Global Launch Sequence in a Post-COVID World
The globe is facing a multitude of governing and legislative changes that will directly affect pharma and pricing in coming years, with many of these changes initiated by the pandemic. As countries become increasingly interconnected, decisions…
Under the Biden Team & Beyond COVID … What Lies Ahead for Healthcare
Posted by
Dr. Richard Stefanacci on January 29, 20211/29/21
While the obvious healthcare focus for the new Biden/Harris Administration will be on controlling the COVID-19 pandemic, it’s a critical time to assess what lies beyond COVID for their attention. To gain a sense of what’s…
Moving Forward in Pharma: Reigniting Revenue for Mature Brands
The world will be moving forward with immeasurable effects from the COVID-19 pandemic, as will the pharmaceutical industry. Fully understanding the impact that the pandemic will have on pharma will take years; however, there are future…
Navigate the Complexity of Proposed CMS Medicaid Rule
In this presentation at MDRP’s virtual summit, Mike Kurland discusses several key regulatory proposals and executive orders and the impact on pharma: Operationalizing Value-Based Contracting – Has the door been opened, and how do we prepare…
CMS Announces Medicare Coverage for FDA-Designated Breakthrough Devices. What Does This Mean?
On August 31, 2020, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule change that would automatically provide national Medicare coverage for FDA-designated Breakthrough Devices for a four-year period immediately upon FDA approval.…
ISPOR 2020 PANEL: Evidence Standards for Medical Device Adoption by U.S. Hospitals
ARE EXISTING REGULATORY EVIDENCE STANDARDS ADEQUATE FOR INFORMING DECISIONS ON MEDICAL DEVICE ADOPTION BY U.S. HEALTHCARE PROVIDERS/HOSPITALS? Virtual ISPOR 2020 | MONDAY, May 18th, 2020 | 11:00 AM ET MODERATOR: Nicole Ferko, MSC, EVERSANA ISSUE: With cost containment…